Sangel Capital

What Sangel Capital does

Sangel Capital (仙瞳资本) is one of the earliest globally-operating, sector-specialized biomedical venture capital firms in China, founded in 2008 and headquartered at Shenzhen Bay Venture Capital Building in Shenzhen's Nanshan District, with additional offices in Beijing, Suzhou, and Chicago. The firm manages a series of RMB and USD-denominated funds focused exclusively on the life sciences sector, including novel drug development (small molecules, biologics, RNAi therapeutics, oncolytic viruses), molecular and precision diagnostics, life-science instrumentation, medical devices, and synthetic biology. Revenue is generated through conventional VC mechanics — management fees on managed funds plus carried interest on portfolio exits — with no public disclosure of fund sizes, AUM, or unit-level economics.

The investment and advisory team is explicitly structured as a hybrid of life-sciences industry experts, scientists, and investment professionals, and Founder Liu Mulong (刘牧龙) is publicly characterized as a "scientist-type VC." This domain depth is reflected in the portfolio, which spans 20+ named companies with notable technical and commercial inflection points: BeyondSpring (NASDAQ: BYSI, plinabulin FDA Priority Review), Sirnaomics (HKEX, post-E valuation $657M), 3D Medicines (>50x valuation growth), Rongzhi Bio (proprietary QuanTOF mass spectrometry platform, 20x valuation growth), Denogene (590M RMB C-round, 300M RMB D-round, STAR Market filer), Ascentawits (AST-3424 NMPA clinical approval across 14 tumor types), Yingmeida Medical (ultra-miniature IVUS+OCT imaging), Huaheng Bio (STAR Market 688639), and Virogin Biotech (oncolytic virus platform, $80M D-round).

Sangel differentiates itself from generalist Chinese VCs through cross-border execution capability: portfolio companies have achieved exits across NASDAQ, STAR Market, and HKEX, and Sangel has co-led or participated in cross-border rounds alongside SDIC Venture Capital, Ping An Ventures, Advantech Capital, Korea Investment Partners, KIP, Legend Capital, and Alibaba Health. The Chicago office specifically supports US deal sourcing and dual-jurisdiction regulatory navigation (FDA + NMPA). Brand credibility is reinforced by 2020-2021 industry rankings — Top 10 Greater Bay Area early-stage VC (Touzhong), Top 10 Most Professional Medical Investment Institutions (LeiFeng), and Top 50 Healthcare Investment Institutions (Chuangbang). Despite operating with a sub-10-person team, the firm demonstrates concentrated value-creation (50x on a single 2012 investment, 20x on a 2015 angel investment) consistent with a specialist, high-conviction investment model.

Name

Sangel Capital

Legal name

深圳仙瞳资本管理有限公司

Website

https://sangelvc.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Sangel Capital (仙瞳资本) is a China-based, sector-specialized biomedical venture capital firm founded in 2008, managing RMB and USD funds across offices in Shenzhen, Beijing, Suzhou, and Chicago, serving early-stage life-sciences companies with capital, regulatory navigation, and dual-jurisdiction (NASDAQ/STAR/HKEX) exit support.

Ownership category

akta.pro rank

Product category

Venture Capital (Biomedical/Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE)

akta.pro secondary industries

Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC), Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Biomedical venture capital
• Life sciences investment
• Healthcare venture funding
• Biotech equity investment
• Innovative drug investment

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management Fees: Sangel Capital generates revenue through management fees charged on managed RMB and USD-denominated venture capital funds focused on the life sciences sector. The firm operates and manages series RMB and USD funds.
2. Performance Carry (Carry from Portfolio Exits): The firm generates carried interest returns from successful portfolio company exits including IPOs on NASDAQ (BeyondSpring), STAR Market (Huaheng Bio), Hong Kong exchanges, and strategic M&A transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Sangel Capital is a specialized biomedical venture capital firm that manages and operates RMB and USD-denominated funds focused on life sciences and healthcare. The firm makes equity investments in early-stage biomedical companies spanning novel drug development (small molecules, RNAi therapeutics), molecular diagnostics, medical devices, and life science instrumentation. Beyond capital, Sangel Capital provides portfolio companies with strategic guidance, regulatory support (FDA/NMPA), international networks, and assistance with cross-border expansion and IPO preparation.

Product overview

Sangel Capital is a professional biomedical venture capital firm that provides investment management services for life technology and healthcare companies. The firm operates series RMB and USD funds, managing investments from early-stage to growth-stage, with offices in Shenzhen, Beijing, Suzhou, and Chicago. The investment portfolio spans innovative drug development, medical devices, diagnostic technologies, and biotechnology platforms across portfolio companies including Sirnaomics (RNAi therapeutics), Sinowis (precision medicine), Virogin (oncolytic viruses), and various medical device innovators.

Differentiator

Problem solved

Functional benefit

Products and services

• RMB-Denominated Biomedical Venture Capital Funds
• USD-Denominated Biomedical Venture Capital Funds

Quantifiable outcome

• Supported BeyondSpring's NASDAQ IPO in March 2017 (NASDAQ: BYSI), one of the first Chinese biotech IPOs on NASDAQ that year
• +4 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered strategic.

• QIAGEN (凯杰公司)strategicStrategic or Co-development PartnerPortfolio company 索元生物 entered into a global co-development partnership with QIAGEN for companion diagnostics (CDx) for DB102 in DLBCL treatment. QIAGEN develops and commercializes the DGM1 CDx test based on its Rotor-Gene Q MDx platform.
• Harvard Medical School / University of BaselstrategicStrategic or Co-development PartnerPortfolio company BeyondSpring collaborated with researchers from Harvard Medical School and University of Basel to elucidate the immunological mechanism of plinabulin, resulting in landmark publications in Cell and Chem journals.
• Junshi Biosciences (君实生物)strategicStrategic or Co-development PartnerPortfolio company Sirnaomics entered into a strategic clinical collaboration with Junshi Biosciences for joint therapy trials combining Junshi's anti-PD-1 antibody (拓益/toripalimab) with Sirnaomics' STP705 (科特拉尼) for melanoma and skin squamous cell carcinoma in both China and the US.
• Rumpus Therapeutics / Aytu BioPharmastrategicStrategic or Co-development PartnerPortfolio company 索元生物 licensed DB102 for vascular Ehlers-Danlos syndrome (vEDS) and other rare genetic diseases to Rumpus Therapeutics/Aytu BioPharma for up to $100M in milestone and royalty payments.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Qiming Venture Partners: China-focused venture firm with a dedicated healthcare/biotech practice and active US-China deal flow; comparable to Sangel in stage focus and life sciences specialization.
• Highlight Capital (弘晖资本): China-focused healthcare/biomedical VC firm investing across innovative drugs, devices, and diagnostics — directly comparable to Sangel in vertical specialization and stage.
• Lake Bleu Capital (清池资本): Healthcare-focused public-and-private investment manager with a strong cross-border China biotech thesis; overlaps with Sangel on private life sciences deals and IPO follow-on participation.
• Lilly Asia Ventures: China- and US-focused biomedical venture capital firm investing in early- and growth-stage life sciences companies with cross-border US-China capability — the closest direct peer to Sangel in thesis, stage, and cross-border structure.
• C-Bridge Capital: China- and US-focused healthcare/biotech investor with cross-border capability and RMB/USD fund structure — directly comparable to Sangel in dual-jurisdiction model.
• 6 Dimensions Capital (通和毓承): Cross-border life sciences investor formed from the merger of China-focused TF Capital and US-focused Frontline BioVentures — one of the closest direct competitors to Sangel's cross-border biomedical VC model.

Broad incumbents

• OrbiMed: Large global healthcare-dedicated investment platform across PE, venture, and royalty/credit — a broad incumbent competing for the same biomedical VC deal flow that Sangel targets.
• Bain Capital Life Sciences: Global life sciences-focused investment platform that invests across venture, growth, and public equities in biotech — comparable broad incumbent in life sciences VC with global footprint.
• Shenzhen Capital Group (深创投): Major Shenzhen-headquartered state-affiliated VC/PE platform with extensive healthcare/biotech exposure; competes with Sangel for early-stage Shenzhen and Greater Bay Area life sciences deals.
• Hillhouse Capital (Healthcare/VC arm): Large multi-stage China-headquartered investment platform with active biomedical/healthcare investing across PE and growth equity — broader in mandate but competes for similar China biotech deal flow and LP relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sangel Capital